OBIO

Orchestra BioMed Holdings, Inc. Ordinary Shares

4.50

USD

OBIO Earnings Reports

Positive Surprise Ratio

OBIO beat 10 of 12 last estimates.

83%

Next Report

Date of Next Report

May 04, 2026

Estimate for Q1 26 (Revenue/ EPS)

$551.57K

-$0.44

Implied change from Q4 25 (Revenue/ EPS)

-98.22%

+238.46%

Implied change from Q1 25 (Revenue/ EPS)

-36.46%

-10.20%

Orchestra BioMed Holdings, Inc. Ordinary Shares earnings per share and revenue

On Mar 12, 2026, OBIO reported earnings of -0.13 USD per share (EPS) for Q4 25, beating the estimate of -0.38 USD, resulting in a 66.33% surprise. Revenue reached 30.92 million, compared to an expected 943.20 thousand, with a 3177.87% difference. The market reacted with a -4.78% price change (close before vs. close after earnings).

Looking ahead to Q1 26, -- analysts forecast an EPS of -0.44 USD, with revenue projected to reach 551.57 thousand USD, implying an increase of 238.46% EPS, and decrease of -98.22% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were Orchestra BioMed Holdings, Inc. Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Orchestra BioMed Holdings, Inc. Ordinary Shares reported EPS of -$0.13, beating estimates by 66.33%, and revenue of $30.92M, 3177.87% above expectations.

How did the market react to Orchestra BioMed Holdings, Inc. Ordinary Shares's Q4 2025 earnings?

The stock price moved down -4.78%, changed from $4.60 before the earnings release to $4.38 the day after.

When is Orchestra BioMed Holdings, Inc. Ordinary Shares expected to report next?

The next earning report is scheduled for May 04, 2026.

What are the forecasts for Orchestra BioMed Holdings, Inc. Ordinary Shares's next earnings report?

Based on -- analysts, Orchestra BioMed Holdings, Inc. Ordinary Shares is expected to report EPS of -$0.44 and revenue of $551.57K for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.